Doseology Sciences Innovates with Feed That Brain Acquisition
Doseology Completes Acquisition of Feed That Brain™
Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70), a leader in precision-formulated oral stimulants, proudly announces the successful acquisition of the "Feed That Brain" division. This move, further outlined in their previous announcement, solidifies the company's commitment to innovation in cognitive performance solutions.
Details of the Acquisition
The acquisition involves the issuance of 175,000 common shares to the vendor, Joseph Mimran & Associates Inc. This transaction reflects a deemed share price of $1.00 each and satisfies the initial payment terms stated in the asset purchase agreement.
Shareholder Implications
The shares issued to the vendor will be subject to a four-month hold period as mandated by Canadian Securities Laws. This measure ensures compliance and maintains the integrity of the investor relations process.
About Doseology Sciences Inc.
Doseology is dedicated to advancing health and performance through innovative products. By engineering precision-formulated oral stimulants, the company optimizes energy levels, enhances focus, and boosts cognitive performance. Their commitment to groundbreaking scientific research and advanced delivery technologies positions them at the forefront of developing next-generation performance solutions.
Company Commitment
Led by CEO Chris Jackson, Doseology's mission is to empower individuals to achieve peak performance. The board is enthusiastic about the potential that the "Feed That Brain" acquisition brings in expanding their product offerings and enhancing their market position.
Future Outlook
This strategic acquisition is expected to enhance Doseology's product portfolio significantly, allowing for greater market penetration and diversification of innovative offerings. The company remains focused on delivering high-quality products that cater to the evolving needs of consumers who seek cognitive enhancement.
Contact Information
For more information regarding this acquisition and the company's future direction, interested parties can reach Doseology Sciences Inc. via the following channels:
Email: [contact information protected]
Website: www.doseology.com
Phone: 604.908.3095
Frequently Asked Questions
What is Doseology Sciences Inc. known for?
Doseology Sciences Inc. specializes in precision-formulated oral stimulants that enhance energy and cognitive performance.
What division did Doseology acquire?
The company acquired the "Feed That Brain" division from Joseph Mimran & Associates Inc.
What are the terms of the acquisition?
The acquisition includes the issuance of 175,000 common shares at a deemed price of $1.00 per share to the vendor.
How does the acquisition impact shareholders?
The shares issued to the vendor will be on a four-month hold, ensuring regulatory compliance and protecting shareholder interests.
Who is the CEO of Doseology Sciences Inc.?
The CEO of Doseology Sciences Inc. is Chris Jackson, who is committed to advancing the company's innovative product lines.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
